Schnabel, Renate B. http://orcid.org/0000-0001-7170-9509
Camen, Stephan http://orcid.org/0000-0003-0224-9208
Knebel, Fabian
Hagendorff, Andreas
Bavendiek, Udo
Böhm, Michael
Doehner, Wolfram
Endres, Matthias
Gröschel, Klaus
Goette, Andreas
Huttner, Hagen B.
Jensen, Christoph
Kirchhof, Paulus
Korosoglou, Grigorios
Laufs, Ulrich
Liman, Jan
Morbach, Caroline
Nabavi, Darius Günther
Neumann-Haefelin, Tobias
Pfeilschifter, Waltraud
Poli, Sven
Rizos, Timolaos
Rolf, Andreas
Röther, Joachim
Schäbitz, Wolf Rüdiger
Steiner, Thorsten http://orcid.org/0000-0002-5080-8222
Thomalla, Götz
Wachter, Rolf
Haeusler, Karl Georg http://orcid.org/0000-0002-6389-5054
Article History
Received: 25 October 2020
Accepted: 1 March 2021
First Online: 18 June 2021
Declarations
:
: RBS has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 648131, from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). RBS has received speaker honoraria and consulting fees from BMS/Pfizer outside this work. FK reports lecture/advisory board fees from Novartis, Bracco, AstraZeneca, Bayer, Alnylam, Sanofi, Shire, Pfizer, Akcea, Canon, all outside this manuscript. UB reports lecture fees/advisory board fees from Abott, Alnylam, Amgen, Astra Zeneca, Novartis outside the submitted work and travel support from Amgen, Bayer, Berlin-Chemie and Pfizer. MB reports fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Servier, Medtronic, ReCor, Vifor, Novartis and Abbott. MB is supported by the Deutsche Forschungsgemeinschaft (DFG, TTR 219, S-01). ME reports grants from Bayer and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Amgen, GSK, Sanofi, Covidien, Novartis, Pfizer, all outside the submitted work. HBH reports research grants by Novartis, Medtronic, UCB Pharma and Portola Pharmaceuticals. HBH reports personal fees from Bayer AG, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, CLS Behring, UCB Pharma and Portola Pharmaceuticals. JL reports lecture fees/advisory board fees from Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb, Daiichi Sankyo, Stryker and Pfizer. CM reports research cooperation with the University of Würzburg and Tomtec Imaging Systems funded by a research grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy, Germany; advisory and speakers honoraria as well as travel grants from Amgen, Tomtec, Orion Pharma, Alnylam, AKCEA, Pfizer, and EBR Systems; principal investigator in trials sponsored by Alnylam and AstraZeneca; financial support from the interdisciplinary center for clinical research—IZKF Würzburg (advanced clinician-scientist program).WP received honoraria and lecture fees from Bayer Healthcare, Pfizer, Stryker neurovascular and research grants from Boehringer Ingelheim and Stryker neurovascular. SP received speaker’s/consulting honoraria from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb/Pizer, Daiichi Sankyo, and Werfen, reimbursement for congress traveling from Bayer, and Boehringer-Ingelheim, and research support from Bristol-Myers Squibb/Pizer, Boehringer-Ingelheim, Daiichi Sankyo, and Helena Laboratories (all outside of the present work). TR received consulting honoraria, speakers’ honoraria and travel support from Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Bayer HealthCare and DaichiiSankyo, outside the submitted work. AR reports lecture honoraria from Pfizer, Boehringer Ingelheim, Bayer, BMS, Berlin Chemie. JR reports lecture fees/advisory board fees from Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Amgen, Pfizer (unrelated to the submitted manuscript). WRS reports research grant Health Economic Research Zentrum, Ferrer. Speakers’ Bureau: Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo Co., Bayer, Pfizer, Medtronic, Ferrer as well as consultant/advisory board fees from Boehringer Ingelheim, Daiichi Sankyo Co., Medtronic. GT reports study grants by Bayer, lecture fees/advisory board fees from Acandis, Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb / Pfizer, Daiichi Sankyo, and Stryker. RW reports grants from Bundesministerium für Bildung und Forschung (BMBF), Deutsches Zentrum für Herz-/Kreislaufforschung, Deutsche Forschungsgemeinschaft, European Union and Medtronic, all outside the submitted work. He received personal fees from AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers-Squibb, CVRX, Daiichi Sankyo, Gilead, Medtronic Novartis, Pfizer, Pharmacosmos, Servier, outside the submitted work. KGH reports study grants by Bayer and Sanofi-Aventis, lecture fees/advisory board fees from Abbott, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Bristol-Myers-Squibb, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Pfizer, Premier Research and Sanofi-Aventis. The other authors report no conflict of interest. Sollte formal vor den COIs von KGH aufgeführt werden.